Abstract
Introduction
Radioactive iodine (RAI) therapy is part of the treatment option for Graves’ disease, and it is widely accepted to be safe. However, some evidence suggests its association to a small increased risk of thyroid cancer and rarely to an aggressive form of thyroid carcinoma.
Case report
Here, we report a case of anaplastic thyroid carcinoma (ATC) following RAI treatment for Graves’ disease. A 48 year-old woman had been diagnosed with Graves’ disease and thyroid nodules. A single RAI treatment had been performed after an unsuccessful medical therapy approach. More than 10 years later, the patient was admitted to our clinic due to dysphonia, weight loss and a rapidly growing neck mass. Thyroid ultrasound and neck computed tomography suggested a thyroid carcinoma and she was diagnosed with a V600E BRAF-mutated ATC. She was given carboplatin, paclitaxel, and radiotherapy. The patient died a few months after the first symptoms of the disease occurred.
Discussion
It is not clear if the occurrence of ATC could be influenced by the RAI therapy for hyperthyroidism. Therefore, we reviewed the different cases and characteristics of ATC after RAI published so far in the literature. Patients were exclusively females, the median age at diagnosis was 66,5 years old (IQR: 51,5–69, range 29–75) and the median time occurring from RAI treatment and ATC diagnosis was 7 years. To our knowledge, here we report the first patient with V600E BRAF-mutation in ATC after RAI for Graves’ disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All authors had full access to all the data in the study and take responsibility for the integrity of the data.
References
Kahaly GJ, Bartalena L, Hegedüs L et al (2018) European thyroid association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 7:167–186
Dobyns BM, Sheline GE, Workman JB et al (1974) Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 38:976–998
Ron E, Doody MM, Becker DV et al (1998) Cancer mortality following treatment for adult hyperthyroidism. JAMA 280:347–355
Hall P, Berg G, Bjelkengren G et al (1992) Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer 50:886–890
Franklyn JA, Maisonneuve P, Sheppard M et al (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet (London, England) 353:2111–2115
Metso S, Auvinen A, Huhtala H et al (2007) Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 109:1972–1979
Gronich N, Lavi I, Rennert G et al (2020) Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study. Thyroid 30(2):243–250
Kitahara CM, Berrington De Gonzalez A, Bouville A et al (2019) association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med 179:1034–1042
Hoffman DA, McConahey WM, Fraumeni JFJ et al (1982) Cancer incidence following treatment of hyperthyroidism. Int J Epidemiol 11:218–224
Shim SR, Kitahara CM, Cha ES et al (2021) Cancer risk after radioactive iodine treatment for hyperthyroidism: a systematic review and meta-analysis. JAMA Netw Open 4:1–14
Williams ED (1986) Relation between 131I therapy for thyrotoxicosis and development of thyroid carcinoma. Lancet. https://doi.org/10.1016/S0140-6736(86)92159-8
Remick SC, Nagaiah G, Hossain A et al (2011) Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. https://doi.org/10.1155/2011/542358
Scheffel RS, Dora JM, Maia AL (2022) BRAF mutations in thyroid cancer. Curr Opin Oncol 34:9–18
Bible KC, Kebebew E, Brierley J et al (2021) American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31:337–386
Riley AS, McKenzie GAG, Green V et al (2019) The effect of radioiodine treatment on the diseased thyroid gland. Int J Radiat Biol. https://doi.org/10.1080/09553002.2019.1665206
Ryödi E, Metso S, Jaatinen P et al (2015) Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism. J Clin Endocrinol Metab 100:3710–3717
Campennì A, Avram AM, Verburg FA et al (2023) The EANM guideline on radioiodine therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-023-06274-5
Russ G, Bonnema SJ, Erdogan MF et al (2017) European thyroid association guidelines for ultrasound malignancy risk stratification of thyroid nodules in adults: the EU-TIRADS. Eur Thyroid J 6:225–237
Narendran N, Luzhna L, Kovalchuk O (2019) Sex difference of radiation response in occupational and accidental exposure. Front Genet 10:1–11
Saenko V (2023) Radiation-related thyroid cancer. Endocr Rev 45(1):1–29
Rivkees SA (2016) Controversies in the management of Graves’ disease in children. J Endocrinol Invest 39:1247–1257
Baker HW (1969) Anaplastic thyroid cancer twelve years after radioiodine therapy. Cancer 23:885–890
Gossage AA, Neal FE, Ross CM et al (1984) Cases of carcinoma of thyroid following iodine-131 therapy for hyperthyroidism. Oncology 41:8–12
Kim SH, Kim HY, Jung KY et al (2013) Anaplastic thyroid carcinoma following radioactive iodine therapy for graves’ disease. Endocrinol Metab 28:61
Al Eyadeh A, Al-Sarihin K, Etewi S et al (2017) Thyroid cancer post radioactive iodine treatment for hyperthyroidism—case series and review of the literature. Endokrynol Pol 68:561–566
Fujikawa M, Okamura K, Sato K et al (1998) Anaplastic transformation of a papillary carcinoma of the thyroid in a patient with Graves’ disease with varied activity of thyrotropin receptor antibodies. Thyroid 8:53–58
Pazaitou-Panayiotou K, Michalakis K, Paschke R (2012) Thyroid cancer in patients with hyperthyroidism. Horm Metab Res Ger 44:255–262
Belfiore A, Russo D, Vigneri R et al (2001) Graves’ disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf) 55:711–718
Author information
Authors and Affiliations
Contributions
All the authors contributed to the study conception and design. Villanova M performed the literature search and data analyses, and drafted the first version of the manuscript. Giubbini R performed data analyses, and critically revised the work for important intellectual content. Di Filippo L and Castellino L aided with interpretation of data and provided substantial contribution to patient’s data. Bolamperti FM provided substantial contribution to patient’s data and Rodella C performed data analyses. All authors revised and approved the final version to be published.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Ethical approval
This is a case report. No ethical approval is required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Villanova, M., di Filippo, L., Bolamperti, F.M. et al. V600E BRAF-mutated anaplastic thyroid carcinoma after radioactive iodine for Graves’ disease: a case report and a review of the literature. Clin Transl Imaging (2024). https://doi.org/10.1007/s40336-024-00643-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40336-024-00643-2